Local authorities no longer require routine PMS studies;GSK does not believe the study would add meaningfully to the safety data already available for Synflorix

The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.

Inclusion Criteria:

• Subjects who the investigator believes that their parents/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol.
• Filipino male or female subjects whose age at the first vaccination with Synflorix™ in this PMS should not be less than 6 weeks of age.
• Filipino male or female subjects who enter the PMS at the second dose should not be less than 10 weeks of age.
• Filipino male or female subjects who enter the PMS at the third dose should not be less than 14 weeks of age.
• Filipino male or female subjects who enter the PMS at the booster dose (i.e. if they have received Synflorix™ in the previous dose/s outside the PMS) should not be less than 10 months of age. The time interval between the primary vaccination and booster dose should be at least 6 months. For the booster dose, subjects who received PCV-7/-13 or Synflorix™ in their primary vaccination series will be allowed to take part in the PMS.
• Written and signed informed consent obtained from the parents/LAR(s) of the child. Where parents/LAR(s) are illiterate, the consent form will be countersigned by a witness.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Acute disease and/or fever at the time of vaccine administration.
• Fever is defined as temperature ≥ 37.5°C (99.5°F) on axillary, infrared or tympanic setting.
• Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
• History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.
• Hypersensitivity to latex (found in syringe-tip cap and plunger).
• Any contraindications as stated in the Prescribing Information.

Healthy Filipino infants and children aged 6 weeks of age to 5 years of age who will receive Synflorix™ as a part of routine practice as per the Prescribing Information in Philippines.